Stocktoria

GeneDx Holdings Corp. WGS

Nasdaq · XNAS · stock · Services-Health Services · website · IPO 2020-09-04

GeneDx Holdings Corp. financials (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Revenue$427.5M$305.4M$202.6M$234.7M$212.2M
Gross profit$298.2M$194.4M$90.0M-$26.8M-$16.6M
R&D expense$72.0M$45.7M$58.3M$86.2M$105.2M
Operating income-$13.1M-$23.2M-$180.6M-$667.7M-$446.1M
Interest expense$3.2M$2.8M
Income tax-$116,000-$343,000-$926,000-$49.1M$0
Net income-$21.0M-$52.3M-$175.8M-$549.0M-$245.4M
EPS (diluted)$-0.73$-1.94$-7.23$-53.63$-2.27
Operating cash flow$33.3M-$28.5M-$180.1M-$319.2M-$190.4M
Free cash flow$14.3M-$34.0M-$185.4M-$326.3M-$199.8M
Cash & equivalents$105.0M$85.2M$99.7M$123.9M$400.6M
Inventory$14.0M$10.7M$8.8M$13.7M$33.5M
Total assets$523.7M$419.4M$418.8M$490.9M$554.1M
Total liabilities$215.5M$174.1M$190.7M$237.2M$166.0M
Shareholders' equity$308.2M$245.2M$228.0M$253.7M$388.1M

Source: SEC EDGAR filings · CIK 0001818331 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.